Vertex Pharmaceuticals (VRTX) Cash from Investing Activities (2009 - 2026)

Vertex Pharmaceuticals has reported Cash from Investing Activities for 18 years, with the latest figure at -$45.8 million in Q2 2026.

• On a quarterly basis, Cash from Investing Activities rose 90.55% year-over-year to -$45.8 million in Q2 2026; TTM through Jun 2026 was -$882.8 million, a 48.38% increase from a year earlier, with the FY2025 full-year figure at -$945.4 million, up 74.92% from the prior year.
• Cash from Investing Activities was -$45.8 million for Q2 2026 at Vertex Pharmaceuticals, up from -$431.9 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $175.6 million in Q4 2022, with the low at -$2.1 billion in Q1 2024.
• Average Cash from Investing Activities over 5 years is -$480.9 million, with a median of -$326.0 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities surged 231.04% in 2022, then tumbled 3495.29% in 2023.
• Over 5 years, Cash from Investing Activities stood at $175.6 million in 2022, then tumbled by 604.84% to -$886.5 million in 2023, then grew by 7.29% to -$821.9 million in 2024, then surged by 64.95% to -$288.1 million in 2025, then surged by 84.1% to -$45.8 million in 2026.
• The last three Cash from Investing Activities figures came in at -$45.8 million (Q2 2026), -$431.9 million (Q1 2026), and -$288.1 million (Q4 2025), per Business Quant data.